Please use this identifier to cite or link to this item:
Title: Synergistic Effects of BAY 60-4552 and Vardenafil on Relaxation of Corpus Cavernosum Tissue of Patients with Erectile Dysfunction and Clinical Phosphodiesterase Type 5 Inhibitor Failure
Authors: Albersen, Maarten
Linsen, Loes 
Tinel, Hanna
Sandner, Peter
Van Renterghem, Koenraad 
Issue Date: 2013
Source: JOURNAL OF SEXUAL MEDICINE, 10 (5), p. 1268-1277
Abstract: Introduction. Overall efficacy rates of phosphodiesterase type 5 inhibitors (PDE5-i) for erectile dysfunction (ED) are 6070%. PDE5-i treatment failures currently have to resort to invasive treatment options for restoration of erectile function. Aims. To assess changes in the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP)/protein kinase (PKG) pathway in human corpus cavernosum (HCC) of PDE5-i nonresponders compared with healthy controls. To evaluate the effects of BAY 60-4552, a stimulator of soluble guanylate cyclase (sGC), and vardenafil on relaxation of HCC strips from PDE5-i nonresponders. Main Outcome Measures. mRNA expression, morphological localization of the NO/cGMP/PKG pathway, and relaxant capacity of both compounds alone or combined. Analysis of variance, t-test or MannWhitney test based upon number of groups and normality of data. Methods. HCC tissues were harvested after consent from individuals undergoing penile prosthesis implantation (patients) and potent patients undergoing transurethral surgery (healthy controls, needle biopsy). HCC tissues of patients were compared with those of healthy controls for the expression of mRNA coding for PDE5A, eNOS, PKG1, PKG2, sGC1, sGC2, sGC1, sGC2, -smooth muscle actin (aSMA) and -actin by quantitative polymerase chain reaction (qPCR). The respective proteins were localized using immunofluorescence. Tissue strips of patients were precontracted with phenylepinephrine followed by incubation with 1M of either vardenafil or BAY 60-4552, or both simultaneously. Results. The main targets in the NO/cGMP/sGC pathway were downregulated in PDE5-i nonresponders. The pathway was morphologically located to HCC smooth muscle, of which the overall content was preserved in ED patients based on aSMA expression. BAY 60-4552 and vardenafil have synergistic effects on relaxation of HCC of PDE5-i nonresponders. The main limitation is the small amount of control tissue precluding functional testing on these samples. Conclusion. Despite downregulation of the NO/cGMP/PKG pathway, combining BAY 60-4552 with vardenafil significantly enhanced relaxation HCC strips of PDE5-i nonresponders.
Notes: Katholieke Univ Leuven Hosp, Lab Expt Urol, Louvain, Belgium. Univ Biobank Limburg, Jessa Hosp, Hasselt, Belgium. Bayer HealthCare, Global Drug Discovery, Wuppertal, Germany. Jessa Hosp, Dept Urol, B-3500 Hasselt, Belgium.
Keywords: Urology & Nephrology;BAY 60-4552; Corpus Cavernosum; Erectile Dysfunction; Vardenafil; Phosphodiesterase Type 5 Inhibitor; Soluble Guanylate Cyclase
Document URI:
ISSN: 1743-6095
e-ISSN: 1743-6109
DOI: 10.1111/jsm.12095
ISI #: 000318237900009
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record


checked on Sep 3, 2020


checked on May 14, 2022

Page view(s)

checked on May 18, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.